# Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

> **NCT01950182** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 392 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Endocrine therapy combined with trastuzumab
- **DRUG:** Chemotherapy combined with trastuzumab

## Key facts

- **NCT ID:** NCT01950182
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-16
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950182, "Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01950182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*